Lipella pharmaceuticals announces abstract publication at 2024 american society of clinical oncology (asco) annual meeting

Pittsburgh, may 29, 2024 (globe newswire) -- lipella pharmaceuticals inc. (nasdaq: lipo) (“lipella,” “our,” “us” or the “company”), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announces an abstract publication at the 2024 american society of clinical oncology (asco) annual meeting, taking place from may 31 - june 4 in chicago, il, and online. lipella's abstract, titled “intravesical administration of pembrolizumab for bladder tumor- a potential strategy to minimize drug toxicity” highlights new preclinical results from lp-50 (intravesical pembrolizumab) in induced murine non-muscle invasive bladder cancer (nmibc).
LIPO Ratings Summary
LIPO Quant Ranking